Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dogwood Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
DWTX
Nasdaq
2836
www.dwtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dogwood Therapeutics, Inc.
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
- Jan 21st, 2025 2:15 pm
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
- Nov 18th, 2024 1:45 pm
DWTX: Phase 2 Long COVID Results Expected Soon
- Nov 11th, 2024 12:00 pm
Q3 2024 Dogwood Therapeutics Inc Earnings Call
- Nov 8th, 2024 7:35 am
Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...
- Nov 8th, 2024 7:15 am
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
- Nov 7th, 2024 12:05 pm
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
- Oct 31st, 2024 1:15 pm
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Oct 30th, 2024 1:15 pm
DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…
- Oct 14th, 2024 11:03 am
Scroll